JPWO2021245223A5 - - Google Patents

Claims (14)

A botulinum toxin injection in a total dose of 50 U to 200 U and a total volume of 0.05 ml to 0.35 ml for injection into the facial area of a subject to treat facial wrinkles. 10. The botulinum toxin injection of claim 1, wherein the botulinum toxin is injected in a total dose of 50U to 175U, or 60U to 150U, or 70U to 125U, or 75U to 100U. 3. The botulinum toxin injection of claim 1 or 2, wherein the botulinum toxin is injected in a total volume of 0.10 ml to 0.35 ml, or 0.10 ml to 0.30 ml, or 0.15 ml to 0.35 ml, or 0.15 ml to 0.30 ml. 4. The botulinum toxin injection of claim 1, wherein the botulinum toxin is injected at a concentration of 150 U/ml to 2000 U/ml, or 200 U/ml to 1500 U/ml, or 250 U/ml to 1000 U/ml, or 300 U/ml to 800 U/ml, or 350 U/ml to 600 U/ml . 5. The botulinum toxin injection of claim 1, wherein the botulinum toxin is injected at 3 to 8 injection points and/or each injection point is injected at a dose of 6 U to 50 U. 6. The botulinum toxin injection of claim 5, wherein the botulinum toxin is injected at each injection site in a volume of 0.02 ml to 0.14 ml, or 0.03 ml to 0.10 ml, or 0.04 ml to 0.06 ml. 7. The botulinum toxin injection preparation according to claim 1, wherein the botulinum toxin is used for treating horizontal lines on the forehead, lines between the glabellar glabellars, lines around the eyes, lines at the crow's feet, lines on the bridge of the nose, nasolabial folds, lines on the upper lip, lines on the lower lip, lines around the corners of the mouth, marionette lines, lines around the mouth, lines at the corners of the mouth, menthol-labial folds and lines on the chin, in particular for treating horizontal lines on the forehead, lines between the glabellar glabellars and lines around the eyes including lines at the crow's feet. 8. The botulinum toxin injection preparation of claim 1, wherein the subject has moderate or severe glabellar lines or severe glabellar lines based on an investigator's assessment using the Facial Wrinkle Scale (FWS) when frowning to the maximum. 9. The botulinum toxin injection of claim 1, wherein the subject is a female subject. 10. The botulinum toxin injection of claim 1, wherein the botulinum toxin is used to treat glabellar lines, and a total dose of 50 U to 150 U and a total volume of 0.15 ml to 0.35 ml of the botulinum toxin is injected into 4, 5, or 6 intramuscular injection points . 11. The botulinum toxin injection of claim 10, wherein the botulinum neurotoxin is used to treat moderate or severe glabellar lines or severe glabellar lines as assessed by an investigator using the Facial Wrinkle Scale (FWS) during maximum frown, and the botulinum toxin is injected at (i) a total dose of 70 U to 130 U and a total volume of 0.15 ml to 0.35 ml, or (ii) a total dose of 80 U to 120 U and a total volume of 0.15 ml to 0.25 ml . 12. The botulinum toxin injection of claim 1, wherein the botulinum toxin is a botulinum neurotoxin complex or a neurotoxic component of a botulinum neurotoxin complex, the neurotoxic component being devoid of any other protein components of the Clostridium botulinum neurotoxin complex, and preferably the botulinum toxin is a botulinum toxin of serotype A. 13. The botulinum toxin injection preparation of any one of claims 1 to 12, wherein the botulinum toxin is administered with an interval of 6 to 9 months between two successive treatment sessions. A composition comprising a botulinum toxin for injection into a facial area of a subject to treat facial wrinkles , the composition comprising a total dose of 50 U to 200 U and a total volume of 0.05 ml to 0.35 ml to treat said facial wrinkles.